Adjunctive Glycine for Obsessive Compulsive Disorder

Not Applicable

Completed

• Conditions: Obsessive Compulsive Disorder
• Interventions: Other: placebo; Drug: glycine

• Registration Number: NCT00405535
• Lead Sponsor: Nathan Kline Institute for Psychiatric Research

Brief Summary

The purpose of this study is to determine whether individuals with obsessive compulsive disorder who will take a preparation of the amino acid glycine in addition to their current treatment, may experience improvement in their symptoms.

Detailed Description

Individuals with obsessive compulsive disorder (OCD) often find inadequate relief, even with the best of currently available treatments. Some evidence suggests the the neurotransmitter glutamate may be a useful target for new treatments for OCD. The amino acid glycine, if given orally in adequate dosages, can have specific effects on one particular glutamate receptor molecule in the brain, that might be helpful with OC symptoms. This randomized, double-blind protocol will have study participants who suffer with OCD take either a glycine preparation or placebo for 12 weeks. Clinical measures (e.g., Y-BOCS, NIMH-OC) will be recorded at each visit to determine whether those taking the glycine experience clinical benefit.

Study Timeline

• Study Start: 2004-06
• Study First Submitted: 2006-11-28
• Study First Submitted QC: 2006-11-28
• Study First Posted: 2006-11-30
• Study Completion: 2006-12
• Status Verified: 2016-12
• Last Update Submitted: 2016-12-15
• Last Update Posted: 2016-12-16

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 24

Inclusion Criteria

• Diagnosis of OCD present for at least 1 year
• Male or female, age 18 to 65
• Stable medication regimen for 12 weeks prior to study entry
• at least moderately severe OC symptoms

Exclusion Criteria

• Active substance use disorder within the last 6 months
• Comorbid schizophrenia, schizoaffective disorder, bipolar disorder, tic disorder, Tourette Disorder, schizotypal personality disorder
• Hoarding as the principal OCD symptom
• Insulin-dependent diabetes mellitus
• Pregnant or breastfeeding

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
B	placebo	placebo powder
A	glycine	glycine powder

Primary Outcome Measures

Name	Time	Method
Y-BOCS (Yale-Brown Obsessive Compulsive Scale)	12 weeks after baseline

Secondary Outcome Measures

Name	Time	Method
CGI-Improvement	12 weeks after baseline
QLS(Quality of Life Scale)	12 weeks after baseline
NIMC-OC scale	12 weeks after baseline
Sheehan Disability Scale	12 weeks after baseline

Trial Locations

Locations (1)

The Nathan Kline Institute for Psychiatric Research; 🇺🇸 Orangeburg, New York, United States